Company Profile

Genetics Institute Inc (AKA: GI)
Profile last edited on: 10/13/22      CAGE: 3WEV0      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

87 Cambridge Park Drive
Cambridge, MA 02140
   (617) 876-1170
Location: Multiple
Congr. District: 07
County: Middlesex

Public Profile

No longer traded since 1996, when American Home products purchased the remaining 60% of the firms stock. Genetics Institute, Inc., a wholly-owned subsidiary of American Home Products Corporation, is a leading biopharmaceutical company engaged in the discovery, development and commercialization of human pharmaceuticals through recombinant DNA and other technologies. The company has a diversified portfolio of commercial, licensed, and proprietary pharmaceutical products at various stages of development, including treatments for anemia, hemophilia, cancer, bone damage, inflammatory conditions and immune system disorders. American Home Products is one of the world's largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of prescription drugs and over-the-counter medicines. It is a global leader in vaccines, biotechnology, agricultural products and animal health care. Founded in 1980, Genetics Institute secured funding through venture capital, private placements and early licensing arrangements, which allowed the Company to build an effective infrastructure while developing a large portfolio of biopharmaceutical product candidates. Genetics Institute has R&D and production facilities in Cambridge and Andover, Massachusetts and offices in Paris, France and Tokyo, Japan

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Over 50M
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1988 2 NIH $300,000
Project Title: Production of human monoclonial antibodies in transgenic mice
1988 2 NIH $550,000
Project Title: Genetic engineering of improved factor VIII product
1987 2 NSF $240,000
Project Title: Stabilization of enzymes by attachment to soluble polymers
1986 1 NIH $50,000
Project Title: Establishment of human hemotopoietic cell lines
1986 1 NIH $50,000
Project Title: Novel probes for efficient genetic disease diagnosis

Key People / Management

  Gabriel Schmergel -- President and CEO

  Thomas Maniatis -- Founder

  Mark Ptashne -- Founder

  J David Rozzell

Company News

There are no news available.